Mirum Pharma director Brege sells $1.26m in shares

Director Laura Brege of Mirum Pharmaceuticals (NASDAQ:MIRM) sold a total of 17,000 shares of common stock on September 11, 2025, for approximately $1.26 million. The sales were executed in two tranches, with 15,509 shares sold at a weighted average price of $74.34, in a range of $73.73 to $74.73, and 1,491 shares sold at a weighted average price of $75.07, in a range of $74.745 and $75.19. The transaction comes as MIRM trades near its 52-week high of $78.09, with the stock showing remarkable strength, up nearly 80% year-to-date. According to InvestingPro analysis, the stock appears to be trading above its Fair Value.

On the same day, Brege also exercised options to acquire 17,000 shares of Mirum Pharmaceuticals common stock at an exercise price of $15.00, for a total value of $255,000.

Following these transactions, Brege directly owns 15,703 shares of Mirum Pharmaceuticals.

In other recent news, Mirum Pharmaceuticals reported strong financial results for the second quarter of 2025, with total revenues reaching $127.8 million. This represents a 64% increase compared to the same period in 2024, exceeding expectations of $107.36 million by a significant margin. The company also reported an earnings per share of -$0.12, which was better than the forecasted -$0.33. Following these results, Mirum Pharmaceuticals has adjusted its 2025 revenue guidance to a range of $490 million to $510 million, indicating a projected 48% year-over-year growth at the midpoint. Analyst firms have responded positively to these developments, with H.C. Wainwright raising its price target for Mirum to $80, maintaining a Buy rating. JMP Securities also increased its price target to $81, citing the strong quarterly results and maintaining a Market Outperform rating. Additionally, Stifel has resumed coverage of Mirum with a Buy rating, highlighting the company’s promising growth opportunities and robust commercial business. These updates reflect the positive momentum and potential growth trajectory for Mirum Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.